Loading...
•
Mar 31, 2024
VYNE Q1 2024 Earnings Report
VYNE reported financial results for Q1 2024 and provided a business update.
Key Takeaways
VYNE Therapeutics reported a net loss of $6.2 million on revenues of $0.1 million for the first quarter of 2024. The company is advancing its VYN201 program towards a Phase 2b trial and received IND clearance for its VYN202 program.
Finalized the design of Phase 2b trial for VYN201 in nonsegmental vitiligo and on track to begin this quarter.
Received IND clearance for oral BD2-selective BET inhibitor, VYN202; anticipate first healthy volunteers to be dosed in Phase 1a SAD/MAD trial this quarter.
Cash, cash equivalents, restricted cash and marketable securities totaled $86.0 million as of March 31, 2024.
VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of March 31, 2024 will be sufficient to fund its operations through the end of 2025.
Revenue by Segment
Forward Guidance
VYNE expects to dose the first subject in the VYN201 Phase 2b trial and the first healthy volunteers in the VYN202 Phase 1a trial this quarter.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...